ALTSTATION.IO

Merck & Co., Inc. (MRK) Stock Analysis

By Nova Skye | AltStation.io | Updated October 25, 2026

Price

$145.01

Change

-1.51%

Market Cap

$357.76B

Avg Volume

10.1M

Company Overview

Merck & Co., Inc. is a major pharmaceutical company based in Rahway, New Jersey, operating in the general drug manufacturing industry. Founded in 1891, the company produces prescription medicines, vaccines, and animal health products for patients, hospitals, veterinarians, and farmers worldwide. Its human health business centers on blockbuster therapies like Keytruda for cancer, vaccines such as Gardasil and Vaxneuvance, and specialty treatments including Winrevair and Bridion. Beyond human medicine, Merck sells companion animal treatments like Bravecto and commercial livestock monitoring and health solutions under brands like Nuflor and Allflex.

Merck holds a dominant position in global healthcare, driven primarily by its massive oncology and vaccine franchises. Its scale and core product lineup provide steady cash flow, but heavy revenue reliance on flagship therapies like Keytruda remains its primary long-term vulnerability. The company operates at the top of the general drug manufacturing space while simultaneously collaborating with major peers like AstraZeneca, Bayer, and Eisai on co-commercialized treatments. Running a dedicated animal health division alongside its prescription pharmaceuticals provides diversified recurring income that narrower biotech firms lack.

Merck is actively positioning itself for the future by expanding its pipeline through targeted licensing deals and clinical collaborations. The company secured a licensing agreement for LaNova’s investigational antibody LM-299 and co-development rights for three Daiichi Sankyo antibody-drug conjugate candidates. It is also partnering with Moderna, Ridgeback Biotherapeutics, and Infinimmune to discover and advance new antibody and therapeutic targets. These moves reflect a clear strategy to build out its next generation of specialty biologics and oncology assets before current revenue drivers lose exclusivity.

Key Financials

Market Cap

$357.76B

Revenue

$66.57B

EBITDA

$28.87B

Gross Margin

75.9%

Profit Margin

4.8%

Revenue Growth

5.1%

Total Cash

$7.14B

Total Debt

$53.91B

Free Cash Flow

$15.17B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

115.09

Forward P/E

15.66

Beta

0.22

52-Week High

$156.92

52-Week Low

$82.01

EPS

$1.26

50-Day Avg

$146.45

200-Day Avg

$125.68

Price/Book

8.54

Technical Analysis

MRK trades at $145.01, placing it 86% of the way from its $79.67 52-week low to its $156.00 high. The stock is 6.88% below that high and 82.34% above the low, so most of the recovery has already happened. Price is 0.05% versus the 20-day moving average of $145.20, while momentum is negative at 0.47% over five trading days and 2.36% over 20 days. Near-term support is $139.54, and resistance is $150.91. The chart is strong over the full year but currently stuck in a short-term consolidation.

Recent News and Developments

Merck-Moderna melanoma therapy cuts recurrence risk 42%

Phase 3 INTerpath-001 data showed intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. The 1,137-patient trial also showed a 38% reduction in distant metastasis or death, with two-year recurrence-free survival of 82.2% versus 70.0%. Source: Merck

EU approves Keytruda-Padcev bladder cancer regimen

The European Commission approved Keytruda plus Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, regardless of cisplatin eligibility. In KEYNOTE-B15, the regimen reduced the risk of progression, recurrence or death by 47% and the risk of death by 35% versus chemotherapy and surgery. Source: Merck

Zacks downgrades Merck to strong sell

Zacks Research downgraded MRK from hold to strong sell in a report issued October 19. The broader tracked consensus remained Moderate Buy, with 17 buy ratings, nine holds, one sell and an average price target of $151.92. Source: MarketBeat

Market Sentiment and Analyst Recommendations

Bull Case

Merck generated $66.57 billion in revenue, with revenue growth of 5.1%. The strongest catalyst is the Phase 3 intismeran-Keytruda trial, which reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. It also reduced distant metastasis or death by 38%, while two-year recurrence-free survival reached 82.2% versus 70.0%. Keytruda plus Padcev received European Commission approval for eligible bladder cancer patients after reducing progression, recurrence or death risk by 47% and death risk by 35%. The analyst recommendation is buy across 25 analysts, with a $158.56 target and a high estimate of $186.00. The reason to buy is straightforward: Merck has positive late-stage oncology data, a new European approval and analyst targets above the current $145.01 price.

Bear Case

The P/E ratio is 115.09, which leaves little room for clinical, regulatory or earnings disappointment. Merck carries $53.91 billion in debt against $7.14 billion in cash, creating a large balance-sheet gap. Erste Group Bank cut its fiscal 2026 EPS estimate from $2.73 to $2.63, below the $2.66 consensus and Merck’s $2.66 to $2.76 guidance range. Zacks also downgraded MRK from hold to strong sell on October 19. The stock fell as much as 3.9% on October 22 when positive melanoma data surfaced early, showing that strong trial results were already reflected in expectations. MRK is only 6.88% below its 52-week high, so the valuation and chart offer limited protection if earnings estimates fall again.

What to Watch

Watch whether MRK holds the $139.54 near-term support level during the next quarter. A move above $150.91 resistance would put the stock closer to its $156.00 52-week high, while a break below support would weaken the chart. Investors should track whether Merck’s fiscal 2026 EPS outlook remains within its $2.66 to $2.76 guidance range after Erste cut its estimate to $2.63. The market also needs to see whether the 42% reduction in melanoma recurrence or death translates into continued confidence after the October 22 selloff. Keytruda plus Padcev’s European approval matters because the supporting trial showed a 47% reduction in progression, recurrence or death and a 35% reduction in death. The clearest bullish confirmation would be stronger momentum, maintained earnings guidance and a sustained move through $150.91.

Analyst Consensus

BUY

Based on 25 analyst opinions

Low Target

$105.00

Mean Target

$158.56

High Target

$186.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

73,000

Earnings & Dividends

Next Earnings

Oct 29, 2026

EPS (Trailing)

$1.26

Dividend Yield

231.0%

Payout Ratio

266.7%

Frequently Asked Questions

Is MRK a good stock to buy?

The recommendation is buy based on 25 analysts, and the average target is $158.56 versus a current price of $145.01. The takeaway is that analysts see upside, but the 115.09 P/E makes the entry price important.

What is MRK’s price target?

The average analyst target is $158.56, with estimates ranging from $105.00 to $186.00. The takeaway is that analyst expectations vary widely.

What is MRK’s 52-week range?

The key data lists a 52-week range of $82.01 to $156.92, while the technical price series shows a low of $79.67 and a high of $156.00. The takeaway is that MRK trades near the upper end under either measure.

What are MRK’s support and resistance levels?

Near-term support is the 30-day low of $139.54, and near-term resistance is the 30-day high of $150.91. The takeaway is that those are the primary levels to watch around the current $145.01 price.

Does MRK pay a dividend?

The provided key and technical data do not include dividend information. The takeaway is that no dividend conclusion can be made from this dataset.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 25, 2026.